Vaxess Technologies

In BioPharma-Reporter’s latest Women in Science Q&A, Vaxess CEO Rachel Sha shares her career journey, why she’s passionate about the work we’re doing at Vaxess, and advice for women interested in pursuing a career in the sciences. Read the full Q&A below: https://lnkd.in/eNdaF2-j

It was an honor to keynote this week's inaugural Boston Biotech Investor Day. I focused on the lessons I've learned over the course of my career to-date, which has spanned?a variety of roles at large biopharma companies, startup investing and advising, and now leading a startup as CEO of Vaxess. In the next few weeks, I plan to summarize the talk and share it here. Thank you to BioLabs, LabCentral, and The Engine Accelerator for hosting! I look forward to attending the event again next year. (photo courtesy of LabCentral)

We’re thrilled to announce that Peter Kolchinsky, PhD, co-founder and managing partner at RA Capital Management, has joined Vaxess’s board of directors. “The benefits of Vaxess’s technology go well beyond addressing the very common and real fear that many of us have of needles,” said Kolchinsky. “Imagine if important medicines like GLP-1s could be administered via a once-weekly patch that you apply to your skin and throw away after a few minutes, with no need for a sharps container or refrigeration. In the case of vaccines, imagine getting a booster patch sent in the mail, sparing you from having to travel to a clinic for a shot. Vaxess is truly reimagining what a transdermal patch can do.” Read more about today's news below. https://lnkd.in/e5QSmVbq

Congratulations to The Engine on raising a $398 million third fund. Vaxess was honored to be mentioned as an Engine portfolio company in the recent Forbes feature about the news. "Vaxess, for example, is working on patches that deliver vaccines and biologics in a way that reduces the need for cold chains and syringes." https://lnkd.in/eQddsdky

Congratulations to the entire Vaxess team for the publication of our first phase 1 clinical trial results for the MIMIX skin patch for vaccines and therapeutics. This specific clinical trial evaluated the “safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.” You can read the full paper below, which details the clinical trial’s success — namely, “the MIMIX MAP platform is safe, well tolerated and elicits robust antibody responses.” The Vaxess team looks forward to continuing to apply the MIMIX skin patch to a range of additional vaccines and therapeutics. https://lnkd.in/gJ98DawK

Vaxess CEO, Rachel Sha, had the pleasure of meeting and learning from many of the amazing thought leaders and pioneers in the biotech space. Thanks to Biotechnology Innovation Organization for hosting another great convention this week!

Thank you to Pulse 2.0 for spreading the good news about our recent funding announcement! https://lnkd.in/eQDXCN6u

Thank you to Drug Delivery Business News for the feature on our recent funding announcement! Read the full article here: https://lnkd.in/dyu9ZG7v

Thank you to Hannah Green at the Boston Business Journal for meeting with new Vaxess CEO, Rachel Sha, to learn more about the transition and the exciting plans she has in store for Vaxess. Read the full article here: https://lnkd.in/gpWwzBCp

Today, Vaxess is announcing $12M in additional funding for its industry-leading skin patch for drug delivery. We’re honored to be backed by an extraordinary team of investors in the vaccine and therapeutic space, including RA Capital Management, Engine Ventures, Global Health Investment Corporation, and Mission BioCapital. After a year where Vaxess has demonstrated feasibility of GLP-1 delivery, and partnered with leading biopharma companies in vaccines (mRNA and non-mRNA), Vaxess will focus on applying the MIMIX skin patch to a range of therapeutics and vaccines. With this additional funding, Vaxess is also announcing that Michael Schrader is stepping down as the company’s CEO, and Rachel Sha is joining the company as CEO. https://lnkd.in/e-UN-Hki